Chief executive officer, uniQure
Appears in 1 story
Leading the company through regulatory review after mixed four-year data
uniQure reported four-year data from its Huntington's gene therapy trial on September 29. The results were mixed: the main composite measure showed 44% slower decline, short of statistical significance, while a functional-capacity measure showed 61% slower decline.
Updated Oct 1
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
